Introduction
Every year the Italian Ministry of Health (MoH) offers an Influenza Immunization Program for all subjects at higher risk of flu complications on the basis of age (≥ 65 years old) or clinical and professional condition. Until 2014-2015 immunization campaign against influenza, Trivalent Inactivated influenza Vaccines (TIVs) were the only vaccines used in Italy. Traditional TIVs contain antigens from three viral strains: A(H1N1), A(H3N2), and one of two B lineages: B(Victoria) or B(Yamagata). Each year, the World Health Organization (WHO) decides which viral strains should be included in the next seasonal influenza vaccine. However, accurately predicting which Blineage strain will predominate in the upcoming season has proved to be a challenging task, resulting in frequent mismatches with the vaccine strain [1] , owing to the co-circulation of both lineages or the predominant circulation of the non-vaccine B-lineage. During mismatch seasons, efficacy and effectiveness against the opposite B lineage are lower [2] [3] [4] [5] [6] [7] [8] . To address the issue of B-mismatch, a new Quadrivalent Inactivated influenza Vaccine (QIV) containing both B-lineage strains has been developed, in order to provide broader protection against influenza. The new QIV was available in Italy [9] and included by the MoH in the national recommendations for the seasonal immunization campaign against influenza 2015-2016 [10] . Recently, a Health Technology Assessment (HTA) Report has shown that, in comparison with TIVs, the new QIV is cost-effective (Incremental Cost-Effectiveness Ratio (ICER) = € 18,883/(QALY) Quality-Adjusted Life-Year) from the Italian National Health Service (NHS) perspective [11] . The objective of the present analysis was to estimate the budget impact of the new QIV after its introduction into the national flu immunization campaign in Italy.
Methods
A budget impact analysis (BIA) was made from the NHS perspective, in order to estimate the financial impact due to the introduction of the QIV into the vaccine mix included by the MoH in the influenza immunization campaign for the 2015-2016 flu season. The BIA included the following input data:
• population eligible for influenza immunization and vaccine coverage (target population); • epidemiology of influenza in Italy;
• efficacy of QIV vs TIV;
• vaccine mix and vaccine cost;
• direct influenza costs. 
Target Population
The population targeted by the national Influenza Immunization Program was calculated on the basis of the Italian population in 2014 [12] . Every year in Italy, the MoH offers free influenza vaccination to all subjects at risk (for clinical/professional reasons) and to all subjects aged ≥ 65 year old, regardless of other risk factors. The prevalence of at-risk subjects eligible for influenza vaccination was calculated from the data collected in 25 EU countries (including Italy) by Ryan et al. [13] . The influenza vaccine coverage data in 2014 were then applied to the Italian general population, in order to estimate the annual number of subjects undergoing influenza vaccination within the national Immunization Program [14, 15] . The target population included in the BIA is summarized in Table I .
Epidemiology of influenza in Italy
The probability of contracting influenza in an unvaccinated population was derived from the study by Turner et al. and is reported in Table II [16] [11] . The prevalence of B-lineage strains circulating during a season was estimated as the average data from ECDC Surveillance Reports from 2003 to 2012 (B-Yamagata = 50.88% and B-Victoria = 49.12%) [11] .
Efficacy of QIV vs TIV
In the present BIA, we assumed that:
• the efficacy of QIV vs TIVs in preventing influenza A viruses was the same; age-specific QIV and TIV efficacy versus influenza A viruses is reported in included in TIVs, (mismatching); these are reported in Table III . In both cases, the efficacy of QIV vs TIVs was derived from the meta-analysis by Tricco et al. [20] ; • the B-mismatch value considered in order to estimate the overall efficacy of TIVs vs influenza B was 49.12%. The overall efficacy of TIVs vs influenza B virus in the present analysis was derived by applying the following formula:
TIVs Overall efficacy vs influenza B-virus = (TIV efficacy in match*B-matching) + (TIV efficacy in mismatch*B-mismatching) For example, if, in subjects aged 5-17 years, the efficacy of TIVs vs B is 77% in the scenario of matching and 52% in the scenario of mismatching, on considering an average TIV B-match of 49.12%, the overall efficacy of TIVs vs influenza B in that age-group is:
TIV Overall Efficacy vs influenza B virus = (77%*100%-49.12%)+(52%*49.12%) = 64% Table IV .
Vaccine mix and vaccine cost

Direct influenza cost
The analysis estimated one-year health resource consumption related to influenza, with or without the introduction of QIV into the National Influenza Immunization program. Table V reports the direct costs included in the analysis and the probabilities that patients with influenza will generate these costs. The analysis also took into account the frequency and the cost of influenza patients with complications:
• the frequency of complications in patients with influenza, regardless of age, was 29.46%; this was estimated from the data reported by Sessa et al. [21] ; • the frequency of complications requiring hospitalization was 11.56% for subjects at risk and 7.15% for subjects not at risk [26] ; • in the analysis, it was assumed that 90.77% of these complications requiring hospitalization were respiratory, and that 9.23% were other complications unrelated to the respiratory tract. 
Results
The objective of this analysis was to estimate the budget impact of the new QIV after its introduction into the National Immunization campaign in Italy.
In the base-case scenario, we assumed that, in the 2015-2016 flu season: Figures 1 and 2 summarize the results from these two additional scenarios versus the base-case. In the No B-mismatch scenario, there was no impact of QIV introduction in preventing influenza cases versus TIVs, owing to the complete match between the Bstrain circulating and the B-strain contained in the TIVs. Nevertheless, the net budget impact in this scenario was favourable, because the incremental cost due to QIV introduction was fully offset by increased use of split vaccine (Market Share (MS) +3%) and the decreased use of intradermal vaccine and adjuvanted vaccine (MS -12%), produced a net saving of € 254,700 in a year. In the Full B-mismatch scenario, the influenza cases avoided through the introduction of QIV was 3,120. In this scenario, the broader protection offered by QIV vs TIVs was maximized by the 100% mismatch between the B-strain circulating and the B-strain contained in the TIVs. The net budget impact in this scenario was highly in favour of the introduction of QIV, with € 1,087.382 saved in one year. The majority of this saving came from the reduction in influenza treatment costs produced by QIV versus TIVs, owing to the full B-mismatch (-€ 832,692).
Discussion
The WHO and European Health Authorities encouraged the development of QIV in order to achieve broader protection against influenza by reducing the impact of 
